Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Keystone, Edward; C. Genovese, Mark; Klareskog, Lars; C. Hsia, E.; Hall, Stephen; C. Miranda, Pedro; Pazdur, J; Bae, S-C; Palmer, William; Zrubek, Julie; Wiekowski, Maria; Visvanathan, Sudha; Wu, Zhixian; U. Rahman, Mahboob

doi:10.1136/ard.2008.099010

Public

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Published in Annals of the Rheumatic Diseases • Dec 9, 2008

Authors:

Edward Keystone

Mark C. Genovese

Lars Klareskog

Abstract

OBJECTIVE: The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. METHODS: Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1,...

Subject

Medicine

Golimumab

Rheumatoid arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!